Impactiviti Daily 120909

TODAY’S NEWS

Novartis’ “son of Glivec” (Tasigna) carrying on the family tradition – Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase…more

Need to count calories as part of your diabetes regimen? Yep – there’s an app for that. Developed by Sanofi-Aventis with InTouch Solutions.

Worried about prostate cancer? There may be an app for that – coffee!

Quick overview of a growing trend – personalized medicine.

RECOMMENDED

Territory Management. Need to train your sales reps in better territory management (and selling skills)? We have vendor/providers for that, in the Impactiviti network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Updated again: Jon Richman’s excellent Dose of Digital Pharma and Healthcare Social Media Wiki. If you want to know what’s going in the world of social media in pharma, here’s your starting point.

Start your day off with a smile. Something about this event at a hockey rink is very heartwarming…